Zevra Therapeutics to Ring Nasdaq Stock Market Opening Bell on Monday, February 9, 2026
Zevra Therapeutics (Nasdaq: ZVRA) will ring the Nasdaq opening bell on Monday, February 9, 2026.
Rhea-AI Summary
Zevra Therapeutics (Nasdaq: ZVRA) will ring the Nasdaq opening bell on Monday, February 9, 2026. CEO Neil F. McFarlane will deliver opening remarks at 9:24 a.m. ET followed by the bell at 9:30 a.m. ET. The ceremony is viewable via Nasdaq's live stream and on the Nasdaq MarketSite Tower in New York.
Positive
- None.
Negative
- None.
Details
News Market Reaction – ZVRA
On Feb 2, the day this news came out, ZVRA closed 4.00% above the previous close.
Data tracked by StockTitan Argus for the Feb 2 session.
Key Figures
- Share price
- $9
- Pre-news current price for ZVRA
- 52-week range
- $6.19–$13.16
- 52-week low and high for ZVRA
- Q3 2025 revenue
- $26.1M
- Quarter ended Sep 30, 2025; up from $3.7M prior year
- Q3 2024 revenue
- $3.7M
- Prior-year quarter comparator for Q3 2025
- Q3 2025 net loss
- $0.5M
- Quarter ended Sep 30, 2025; vs $33.2M loss prior year
- 9M 2025 revenue
- $72.3M
- Nine months ended Sep 30, 2025
- 9M 2025 net income
- $71.1M
- Nine months ended Sep 30, 2025, aided by voucher sale
- Priority voucher gain
- $148.3M
- Gain from selling a priority review voucher, 9M 2025
Historical Context
-
Multiple MIPLYFFA analyses presented at WORLDSymposium for NPC data visibility.
-
Management presentation and investor meetings at J.P. Morgan Healthcare Conference.
-
Distribution agreement with Uniphar to broaden MIPLYFFA access outside Europe.
-
Stock option grants to new employees under 2023 inducement award plan.
-
Appointment of Alicia Secor to board and retirement of Wendy Dixon.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CELEBRATION, Fla., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that it has been invited to ring the Nasdaq opening bell on Monday, February 9, 2026. Neil F. McFarlane, Zevra's President and Chief Executive Officer, will deliver opening remarks at 9:24 a.m. followed by the bell ringing at 9:30 a.m. ET, signifying the start of the day's trading session.
The opening bell ceremony can be seen live at https://www.nasdaq.com/marketsite/bell-ringing-ceremony and on the Nasdaq MarketSite Tower at 43rd and Broadway in New York, NY.
About Zevra Therapeutics, Inc.
Zevra Therapeutics, Inc. is a purpose-driven, commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases. The company’s commercialization of its lead product, marketed in the U.S. for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disorder, provides a strong corporate foundation and validates its ability to advance therapies. In addition, the company is broadening access through geographic expansion opportunities and has a pipeline of rare disease programs. Zevra is a patient-centric organization guided by our values of accountability, integrity, innovation and courage, with the goal of creating long-term value for patients, partners, and shareholders.
For more information, please visit www.zevra.com or follow us on X and LinkedIn.
Investor Contact
Nichol Ochsner
+1 (732) 754-2545
nochsner@zevra.com
Media Contact
Julie Downs
+1 (508) 246-3230
jdowns@zevra.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.